Pre-term deliveries due to COVID-19 could be avoided by studying EHRs

Newswise — Using electronic health record data to simulate drug trials for pregnant patients could one day offer a solution to the current practice of delivering babies, even if they are pre-term, if the mother contracts COVID-19, according to a position paper published in Nature Medicine

Pregnant patients have typically been excluded from drug trials out of concern for fetal safety. And when human health is on the line, drug studies assessing fetal safety in animal models may be viewed as far from definitive. Due to sheer lack of data concerning implications for fetal and maternal safety, clinicians are often unsure about prescribing drugs to pregnant patients.

A position paper led by first author Anup Challa and senior author David Aronoff, MD, director, Division of Infectious Diseases at Vanderbilt University Medical Center, outlines how these deficits can lead to undertreatment of chronic and acute illness in pregnant patients, while also posing additional risk of adverse drug reactions. 

"Pregnant patients are an especially vulnerable population, since exposure to many common drugs could harm their unborn children,” said Challa, principal investigator for MADRE and student worker, Vanderbilt Drug Repurposing System. “Further complicating this problem is the fact that pregnant patients are not allowed to enroll in clinical trials, given the ethical issues that a harmful drug reaction in their fetus could pose.

“These factors have significantly reduced quality of care for pregnant patients with COVID-19, as the current guidance to OB/Gyns is to deliver pregnant patients if they contract COVID-19 - even if the patients are significantly pre-term. This could significantly harm their fetuses, and recent case reports have shown that COVID-19 transmission occurs in utero if not treated in the mother,” he added.

Challa and Aronoff propose that using electronic health record data to emulate randomized controlled trials could offer an alternative to delivering all pregnant patients with COVID-19.

Used to compare treatments, these trials involve enrollment of subjects who undergo interventions carried out in real time. In contrast, target trials are a type of observational study that simulates the trial through retrospective analysis of existing clinical data.

“We could identify therapeutics that are safe for use in these patients by using high-powered algorithms like machine learning to learn from cases in which pregnant patients have been exposed to current therapeutic candidates and understand how much risk they pose to a fetus,” Aronoff said.  

Vanderbilt University Medical Center has electronic health records for more than 2 million patients, which allows investigators to design and conduct “trials” that simulate not only a real trial’s treatment strategies (drug versus no drug) and outcomes, but also eligibility criteria and random assignment to treatment at baseline. 

Such trials are arguably “the only ethical way to gather human drug exposure data for pregnant people on a significant scale and across all classes of drugs,” the authors said.

“If expanded, the Vanderbilt platform of target trials may offer an alternative to delivering all pregnant patients with COVID-19 by identifying therapeutics that are safe,” Challa said. “Without a good understanding of safety for these drugs, we might be missing opportunities to treat COVID-19 in pregnant patients." 

In addition to Challa and Aronoff, co-authors include Robert Lavieri, PhD, Ethan Lippmann, PhD, Lisa Bastarache, MS, Jill Pulley, MBA, and Jeffery Goldstein, MD, PhD.

 

 

 

 

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 5429
Released: 16-Apr-2021 4:10 PM EDT
Rutgers Expert Addresses Questions on COVID-19 Vaccine Rollout and Variant Issues
Rutgers University-New Brunswick

Stanley H. Weiss, an epidemiologist in infectious and chronic diseases, and a professor at the Rutgers New Jersey Medical School and the Rutgers School of Public Health, talks about vaccine side effects, the hesitancy that still exists and why it is important to get vaccinated when it’s your turn.

Released: 16-Apr-2021 3:15 PM EDT
Studies suggest people with blood cancers may not be optimally protected after COVID-19 vaccination
American Society of Hematology (ASH)

Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.

Newswise: Simulations reveal how dominant SARS-CoV-2 strain binds to host, succumbs to antibodies
Released: 16-Apr-2021 2:35 PM EDT
Simulations reveal how dominant SARS-CoV-2 strain binds to host, succumbs to antibodies
Los Alamos National Laboratory

Large-scale supercomputer simulations at the atomic level show that the dominant G form variant of the COVID-19-causing virus is more infectious partly because of its greater ability to readily bind to its target host receptor in the body, compared to other variants.

Newswise: 262279_web.jpg
Released: 16-Apr-2021 2:15 PM EDT
Experimental antiviral for COVID-19 effective in hamster study
NIH, National Institute of Allergy and Infectious Diseases (NIAID)

The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.

Newswise:Video Embedded forum-tackles-vaccine-hesitancy-in-the-black-community
VIDEO
Released: 16-Apr-2021 1:25 PM EDT
Forum Tackles Vaccine Hesitancy in the Black Community
Cedars-Sinai

Leading healthcare and faith leaders addressed key issues that are contributing to vaccine hesitancy in Black communities during a national online discussion this week, explaining that a lack of access to healthcare, concerns over vaccine safety, and religious beliefs are keeping many from getting COVID-19 vaccines.

Newswise: COVID-19: Scientists identify human genes that fight infection
Released: 16-Apr-2021 1:10 PM EDT
COVID-19: Scientists identify human genes that fight infection
Sanford Burnham Prebys Medical Discovery Institute

Scientists at Sanford Burnham Prebys have identified a set of human genes that fight SARS-CoV-2 infection, the virus that causes COVID-19. Knowing which genes help control viral infection can greatly assist researchers’ understanding of factors that affect disease severity and also suggest possible therapeutic options. The genes in question are related to interferons, the body’s frontline virus fighters.

Newswise: Study of More Than 3,000 Members of the US Marine Corps. Reveals Past COVID-19 Infection Does Not Fully Protect Young People Against Reinfection
Released: 16-Apr-2021 11:35 AM EDT
Study of More Than 3,000 Members of the US Marine Corps. Reveals Past COVID-19 Infection Does Not Fully Protect Young People Against Reinfection
Mount Sinai Health System

Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.

Released: 15-Apr-2021 8:45 PM EDT
Beyond Boundaries: R Adams Cowley Shock Trauma Center Celebrates Heroes
University of Maryland Medical Center

More than 65 first responders and top trauma medicine professionals who saved the lives of two critically ill patients were honored tonight at the 31st annual R Adams Cowley Shock Trauma Celebration of Heroes. Funds raised by the virtual event will support the Center for Critical Care and Trauma Education.

Released: 15-Apr-2021 4:10 PM EDT
Penn Study Suggests Those Who Had COVID-19 May Only Need One Vaccine Dose
Perelman School of Medicine at the University of Pennsylvania

New findings from Penn suggest that people who have recovered from COVID-19 may only need a single mRNA vaccine dose. However, those who did not have COVID-19 did not have a full immune response until after a second vaccine dose, reinforcing the importance of completing the two recommended doses.


Showing results

110 of 5429

close
1.2508